Tralokinumab and lebrikizumab are mAbs that target IL-13 directly and have recently been approved as additional treatment options for adolescents and adults (≥12 years) with moderate-to-severe AD inadequately controlled by topical therapies (tralokinumab: EMA 2021; FDA 2021; lebrikizumab: FDA 2023; EMA 2023). Here, IL13 is linked to Alzheimer disease.